论文部分内容阅读
目的：对急性淋巴细胞白血病（ＡＬＬ）完全缓解期骨髓白血病细胞的临床意义进行较深入的研究。方法：对２７ 例ＡＬＬ患者治疗前后的骨髓进行细致的形态学分析，并对白血病细胞的消长进行跟踪研究。结果：诱导缓解结束后１５ ｄ 复查骨髓判断疗效较为准确。第１ 次确定完全缓解时骨髓白血病细胞比例与持续完全缓解时间呈负相关。缓解期白血病细胞比例轻度增高者如治疗及时，部分仍可恢复缓解。结论：对ＡＬＬ的完全缓解标准应从严掌握。原幼淋巴细胞达５％ ～２０％ 时，可判断为复发趋势。识别及监测缓解期骨髓白血病细胞对维持完全缓解、延长生存期有重要意义。
Objective: To investigate the clinical significance of myeloid leukemia cells in the complete remission stage of acute lymphoblastic leukemia (ALL). METHODS: Detailed morphological analysis of the bone marrow of 27 patients with ALL before and after treatment was performed, and the growth and decline of leukemia cells were followed. Results: After 15 days after the induction of remission, it was more accurate to review the bone marrow. The first determination of complete remission when the proportion of myeloid leukemia cells was negatively correlated with the duration of complete remission. The slight increase in the proportion of leukemia cells in the remission phase can be restored and relieved if treated in a timely manner. Conclusion: The standard of complete remission for ALL should be strictly controlled. When the original young lymphocytes reach 5% to 20%, the recurrence tendency can be judged. Identifying and monitoring remission stage myeloid leukemia cells is important for maintaining complete remission and prolonging survival.